Non-high-density lipoproteins cholesterol and cardiometabolic diseases

Abstract

   At the present stage, non-high-density lipoprotein cholesterol (non-HDL-C) is intensively studied as a predictor of mortality from cardiovascular diseases. An increase in non-HDL-C content is associated with insulin resistance, which is a pathogenetic factor in the development of atherogenic (mixed) dyslipidemia, which is typical for people with metabolic syndrome (MS) and type 2 diabetes mellitus (TDM2). This review analyzes trends in non-HDL-C level since 1985 in foreign countries and in the Russian Federation. Based on the results of international epidemiological studies, conclusions are substantiated about the possibility of predicting the risk of developing MS and type 2 diabetes using the non-HDL-C. The necessity of conducting prospective cohort studies in the Russian population aimed at assessing the role of non-HDL-C in the early diagnosis of MS and TDM2 is shown. The search for literary sources in the electronic information databases eLIBRARY.RU and PubMed. The analysis included studies published from 1990 to 2023.